Twice-daily budesonide inhalation suspension in infants and children < 4 and > or = 4 years of age with persistent asthma.
A retrospective analysis, based on a randomized, placebo-controlled, 12-week study in children 6 months to 8 years of age with persistent asthma, was performed to compare the efficacy and safety of budesonide inhalation suspension 0.25 mg and 0.5 mg twice daily vs. placebo in children < 4 and > or = 4 years of age. Both age groups demonstrated significant (p < or = 0.050) improvement in nighttime and daytime asthma symptom scores and decreased bronchodilator use compared with placebo. In addition, the safety profile of twice-daily budesonide inhalation suspension was favorable in both age groups.
Mendelson
Louis
L
Connecticut Allergy and Asthma Center, West Hartford 06119, USA.
Cook
David
D
Cruz-Rivera
Mario
M
Fitzpatrick
Sherahe
S
Smith
Joseph A
JA
D000280:Administration, Inhalation; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D019819:Budesonide / Q000008:administration & dosage*; D002675:Child, Preschool; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies
D001993:Bronchodilator Agents; D019819:Budesonide